TRCT
ACHV icon

Tower Research Capital (TRC)’s Achieve Life Sciences ACHV Stock Holding History

Tower Research Capital (TRC)’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.6K Buy
+2,994
New +$14.3K ﹤0.01% 3575
2026
Q1 		– Sell
-2,826
Closed -$14K – 5081
2025
Q4 		$14K Buy
+2,826
New +$12.3K ﹤0.01% 3371
2025
Q3 		– Sell
-4,586
Closed -$10.4K – 5193
2025
Q2 		$10.4K Buy
4,586
+1,098
+31% +$3.13K ﹤0.01% 3952
2025
Q1 		$9.31K Sell
3,488
-4,057
-54% -$12.6K ﹤0.01% 3795
2024
Q4 		$26.6K Buy
7,545
+4,905
+186% +$22.2K ﹤0.01% 2974
2024
Q3 		$12.5K Buy
2,640
+2,347
+801% +$10.7K ﹤0.01% 3581
2024
Q2 		$1.38K Sell
293
-2,849
-91% -$13.7K ﹤0.01% 5164
2024
Q1 		$14.3K Buy
3,142
+430
+16% +$1.91K ﹤0.01% 3320
2023
Q4 		$11.2K Sell
2,712
-906
-25% -$3.95K ﹤0.01% 4153
2023
Q3 		$15.6K Sell
3,618
-15,820
-81% -$79.7K ﹤0.01% 3606
2023
Q2 		$101K Buy
19,438
+15,792
+433% +$111K ﹤0.01% 2021
2023
Q1 		$25K Buy
3,646
+1,570
+76% +$7.46K ﹤0.01% 3187
2022
Q4 		$5K Sell
2,076
-600
-22% -$1.54K ﹤0.01% 4820
2022
Q3 		$9K Sell
2,676
-217
-8% -$1.04K ﹤0.01% 4625
2022
Q2 		$14K Buy
2,893
+1,735
+150% +$11.8K ﹤0.01% 4122
2022
Q1 		$9K Buy
1,158
+1,058
+1,058% +$7.88K ﹤0.01% 4422
2021
Q4 		$1K Sell
100
-1,184
-92% -$9.3K ﹤0.01% 5771
2021
Q3 		$11K Buy
1,284
+976
+317% +$7.66K ﹤0.01% 4199
2021
Q2 		$3K Sell
308
-1,071
-78% -$10.2K ﹤0.01% 4895
2021
Q1 		$16K Buy
1,379
+996
+260% +$11.8K ﹤0.01% 4039
2020
Q4 		$3K Buy
+383
New +$3.24K ﹤0.01% 4773
2018
Q4 		– Sell
-25
Closed -$2K – 3771
2018
Q3 		$2K Buy
+25
New +$1.58K ﹤0.01% 3394
2016
Q1 		– Hold
0
– – – 4032
2015
Q4 		– Hold
0
– – – 4401
2014
Q3 		– Sell
-1
Closed -$4K – 4362
2014
Q2 		$4K Hold
1
– – ﹤0.01% 2963
2014
Q1 		$18K Hold
1
– – ﹤0.01% 1982
2013
Q4 		$10K Hold
1
– – ﹤0.01% 2957
2013
Q3 		$18K Sell
1
-1
-50% -$20.7K ﹤0.01% 2758
2013
Q2 		$47K Buy
+2
New +$44.7K ﹤0.01% 984

Other funds holding ACHV

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Tower Research Capital (TRC)'s ACHV Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Achieve Life Sciences (ACHV) in Q2 2026: 2,994 shares worth $19.6K. The stake represents ﹤0.01% of the portfolio and ranks #3575 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in ACHV as recently as Q4 2025.

Tower Research Capital (TRC) first reported a position in ACHV in Q2 2013 and has held it in 27 quarters since. The position peaked at $101K in Q2 2023. 111 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

  • Tower Research Capital (TRC) held 2,994 shares of Achieve Life Sciences worth $19.6K as of Q2 2026.
  • Achieve Life Sciences was a new Tower Research Capital (TRC) position in Q2 2026.
  • Achieve Life Sciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3575 holding.
  • Tower Research Capital (TRC) first reported a position in Achieve Life Sciences in Q2 2013 and has held it in 27 quarters since.
  • Tower Research Capital (TRC)'s Achieve Life Sciences position peaked at $101K in Q2 2023.
  • 111 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.